Piper Sandler Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $456
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $450 to $456.
May 07, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target to $456.
The increase in the price target by Piper Sandler, a reputable financial services firm, suggests a positive outlook on Vertex Pharmaceuticals' stock. This adjustment reflects an expectation of higher future stock performance, potentially influencing investor sentiment and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100